TVGN Tevogen Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1860871 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY26.3%
TTM EPS YoY23.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-571.7%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets421.4%
Debt / equity—
Current ratio0.13x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.43x
Accruals ratio-325.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $2.96M | $3.28M | $3.13M | $2.11M | $3.11M | $2.70M | $3.20M | $2.84M |
| SG&A expense | $3.94M | $2.38M | $2.27M | $2.50M | $2.62M | $2.74M | $7.16M | $6.53M |
| Operating income | -$6.90M | -$5.66M | -$5.40M | -$4.61M | -$5.73M | -$5.44M | -$10.36M | -$9.36M |
| Interest expense | — | — | — | — | — | — | $24,571 | $15,798 |
| Net income | -$7.00M | -$5.76M | -$5.45M | -$4.68M | -$5.73M | -$5.50M | -$10.37M | -$9.44M |
| EBITDA | -$6.89M | -$5.63M | -$5.37M | -$4.55M | -$5.73M | -$5.35M | -$10.32M | -$9.32M |
| EPS (basic) | -1.76 | -1.52 | -1.61 | — | -1.50 | -1.71 | -3.25 | — |
| EPS (diluted) | -1.76 | -1.52 | -1.61 | — | -1.50 | -1.71 | -3.25 | — |
| Weighted avg. shares (diluted) | 4.10M | 3.83M | 3.49M | — | 3.92M | 3.29M | 3.23M | — |
| Banking | ||||||||
| Net interest income | -$99,950 | -$98,387 | -$71,166 | -$70,674 | -$62,340 | -$38,033 | -$24,571 | -$15,798 |
| Balance sheet | ||||||||
| Cash & equivalents | $144,713 | $1.08M | $692,305 | $552,372 | $1.04M | $685,229 | $1.97M | $1.28M |
| Current assets | $841,136 | $2.01M | $2.14M | $1.54M | $2.12M | $2.06M | $3.08M | $2.36M |
| PP&E, net | $95,539 | $109,772 | $140,040 | $170,308 | $163,930 | $164,448 | $255,889 | $296,442 |
| Total assets | $3.51M | $4.73M | $4.92M | $4.38M | $4.49M | $4.27M | $4.07M | $3.46M |
| Current liabilities | $6.37M | $6.15M | $7.27M | $7.07M | $6.74M | $8.08M | $8.72M | $9.04M |
| Total liabilities | $14.81M | $13.62M | $14.76M | $12.62M | $12.32M | $13.75M | $11.79M | $10.14M |
| Shareholders' equity | -$11.29M | -$8.89M | -$9.84M | -$8.23M | -$7.82M | -$9.48M | -$7.72M | -$6.67M |
| Shares outstanding | 15.74M | 4.26M | 4.17M | 4.02M | 197.39M | 193.69M | 183.89M | 3.56M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.96M | -$3.01M | -$2.73M | -$2.18M | -$3.65M | -$3.19M | -$3.31M | -$3.05M |
| Financing cash flow | $1.02M | $3.40M | $2.87M | $1.76M | $4.00M | $1.90M | $4.00M | $2.00M |
| Depreciation & amortization | $14,233 | $30,268 | $30,268 | $58,061 | $518 | $91,441 | $40,553 | $40,552 |
| Stock-based compensation | $4.50M | $3.29M | $2.85M | $2.45M | $3.24M | $3.24M | $7.29M | $6.96M |
Free plan shows the latest 8 periods; Pro shows all 21 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.